Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer

NACompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

June 19, 2018

Study Completion Date

June 19, 2018

Conditions
Early Gastric Cancer or Gastric Adenoma
Interventions
DRUG

Arm1: Statin

"Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."

DRUG

Arm2: Placebo

"Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."

Trial Locations (1)

120-752

Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT01813994 - Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer | Biotech Hunter | Biotech Hunter